The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study
Abstract
Previous studies examining the involvement of oxidative stress in the substantia nigra in Parkinson's disease have measured terminal products of lipid peroxidation or the function of antioxidant defense systems. We report a more specific early marker of lipid peroxidation, lipid hydroperoxides, in a high‐performance liquid chromatography (HPLC) and electron spin resonance (ESR) investigation. HPLC‐chemiluminescent detection revealed two classes of lipid hydroperoxides in brain tissue extracts–free fatty acid hydroperoxides and cholesterol lipid hydroperoxides. Only cholesterol lipid hydroperoxides were consistently detected in all tissue extracts. Cholesterol lipid hydroperoxides had a 10‐fold increase in the Parkinson's disease substantia nigra compared to control subjects. ESR detection of radical degradation products, including those of lipid hydroperoxides, in nigral homogenates incubated with the spin trap N‐t‐butyl‐α‐phenyl nitrone (PBN) showed a marked variation in ESR signal between tissues. Despite the increased levels of lipid hydroperoxides in parkinsonian substantia nigra, there was no overall difference in ESR signal intensity between nigral tissues from controls and from patients with Parkinson's disease. The increased levels of an early component of the peroxidation chain in substantia nigra in Parkinson's disease support the hypothesis of a continuous toxic process involving oxygen radical activity. However, using previously frozen tissue, ESR evidence for increased radical formation could not be demonstrated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Self-citationBasal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Self-citationTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Self-citationDEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043
Self-citationIncreased nigral iron content in postmortem parkinsonian brain
Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963
Self-citationCENTRAL CERVICAL CORD SYNDROME AFTER HEADING A FOOTBALL
Scoppetta, C., & Vaccario, M. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92517-5 · Cited by 753
Parkinson's disease: A disorder due to nigral glutathione deficiency?
Perry, T. L., Godin, D. V., & Hansen, S. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90390-1 · Cited by 753
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G., & Youdim, M. B. H. (1988) · Journal of Neural Transmission · doi:10.1007/bf01244786 · Cited by 752
Schapira, A. H. V., Mann, V. M., Cooper, J. M., Dexter, D., Daniel, S. E., Jenner, P., Clark, J. B., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673
Self-citation
Cited by
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Self-citationHalliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,440
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161
Self-citationHanschmann, E.-M., Godoy, J. R., Berndt, C., Hudemann, C., & Lillig, C. H. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4599 · Cited by 677
Etiology and pathogenesis of Parkinson's disease
Schapira, A. H., & Jenner, P. (2011) · Movement Disorders · doi:10.1002/mds.23732 · Cited by 657
Self-citationKim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655
Neuroprotection by the Metabolic Antioxidant α-Lipoic Acid
Packer, L., Tritschler, H. J., & Wessel, K. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00269-9 · Cited by 639
Reactive Oxygen Species in the Regulation of Synaptic Plasticity and Memory
Massaad, C. A., & Klann, E. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3208 · Cited by 635
Chen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease
BEAL, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 523
α-Synuclein: Membrane Interactions and Toxicity in Parkinson's Disease
Auluck, P. K., Caraveo, G., & Lindquist, S. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.042308.113313 · Cited by 519
Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins
Abuja, P. M., & Albertini, R. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00393-x · Cited by 452
Glutathione metabolism and Parkinson's disease
Smeyne, M., & Smeyne, R. J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.001 · Cited by 435
Oxidative damage in neurodegenerative disease
Jenner, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92347-7 · Cited by 418
Self-citationGlutathione, iron and Parkinson’s disease
Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S., & Andersen, J. K. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01174-7 · Cited by 396
Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Lee Mosley, R., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., Laurie, C., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 387
Lipid peroxidation and neurodegenerative disease
Reed, T. T. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.027 · Cited by 379
Martin-Bastida, A., Ward, R. J., Newbould, R., Piccini, P., Sharp, D., Kabba, C., Patel, M. C., Spino, M., Connelly, J., Tricta, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01402-2 · Cited by 379
Self-citationLevodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders · doi:10.1002/mds.20243 · Cited by 370
Self-citationMitochondria in Neurodegeneration: Acute Ischemia and Chronic Neurodegenerative Diseases
Fiskum, G., Murphy, A. N., & Beal, M. F. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199904000-00001 · Cited by 350
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model
Sanders, L. H., & Timothy Greenamyre, J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.003 · Cited by 345
Mattson, M. P. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01188-0 · Cited by 344
Role of Oxidative Stress and Antioxidants in Neurodegenerative Diseases
Rao, A. V., & Balachandran, B. (2002) · Nutritional Neuroscience · doi:10.1080/1028415021000033767 · Cited by 336
Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review)
Guo, J., Zhao, X., Li, Y., Li, G., & Liu, X. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3406 · Cited by 335
Patel, B. N., & David, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.32.20185 · Cited by 327
ESPOSITO, E., ROTILIO, D., DIMATTEO, V, DIGIULIO, C., CACCHIO, M., & ALGERI, S. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00078-7 · Cited by 326
Glutamate and Parkinson’s disease
Blandini, F., Porter, R. H. P., & Greenamyre, J. T. (1996) · Molecular Neurobiology · doi:10.1007/bf02740748 · Cited by 323
Nrf2—a therapeutic target for the treatment of neurodegenerative diseases
Johnson, D. A., & Johnson, J. A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.147 · Cited by 321
Drechsel, D. A., & Patel, M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.02.008 · Cited by 314
The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis
Santana-Codina, N., Gikandi, A., & Mancias, J. D. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-62026-4_4 · Cited by 301
Glutathione‐related enzymes in brain in Parkinson's disease
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360306 · Cited by 296
Self-citationThe Nrf2–ARE cytoprotective pathway in astrocytes
Vargas, M. R., & Johnson, J. A. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001094 · Cited by 291
Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases
Gan, L., & Johnson, J. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.011 · Cited by 288
Calabrese, V., Bates, T. E., & Stella, A. M. G. (2000) · Neurochemical Research · doi:10.1023/a:1007604414773 · Cited by 284
Mitochondria and degenerative disorders
Orth, M., & Schapira, A. H. V. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1425 · Cited by 280
Beal, M. F. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041772.74810.92 · Cited by 277
Le, W.-D., Rowe, D., Xie, W., Ortiz, I., He, Y., & Appel, S. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08447.2001 · Cited by 275
Nutrition, Brain Aging, and Neurodegeneration: Table 1.
Joseph, J., Cole, G., Head, E., & Ingram, D. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3520-09.2009 · Cited by 264
Calabrese, V., Scapagnini, G., Giuffrida Stella, A. M., Bates, T. E., & Clark, J. B. (2001) · Neurochemical Research · doi:10.1023/a:1010955807739 · Cited by 263
“(114) reported a 31–35% increase in the total iron content in parkinsonian SN compared to control tissue, which was associated with decreased levels of the iron storage protein ferritin, contrasting with a significant decrease of iron binding protein levels in the CSF.”
BackgroundOxidative damage in Parkinson disease: Measurement using accurate biomarkers
Seet, R. C. S., Lee, C.-Y. J., Lim, E. C. H., Tan, J. J. H., Quek, A. M. L., Chong, W.-L., Looi, W.-F., Huang, S.-H., Wang, H., Chan, Y.-H., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.026 · Cited by 257
Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity
Jha, N., Jurma, O., Lalli, G., Liu, Y., Pettus, E. H., Greenamyre, J. T., Liu, R.-M., Forman, H. J., & Andersen, J. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000120200 · Cited by 252
Wang, J.-Y., Wen, L. L., Huang, Y.-N., Chen, Y.-T., & Ku, M.-C. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778343109 · Cited by 250
Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease
Foy, C. J. (1999) · QJM · doi:10.1093/qjmed/92.1.39 · Cited by 235
Sohmiya, M., Tanaka, M., Wei Tak, N., Yanagisawa, M., Tanino, Y., Suzuki, Y., Okamoto, K., & Yamamoto, Y. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.007 · Cited by 143
Pan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131
Morris, G., Anderson, G., Berk, M., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8477-8 · Cited by 96
Functional relevance of ceruloplasmin mutations in Parkinson's Disease
Hochstrasser, H., Tomiuk, J., Walter, U., Behnke, S., Spiegel, J., Krüger, R., Becker, G., Riess, O., & Berg, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3486fje · Cited by 87
Xu, C.-L., Qu, R., Zhang, J., Li, L.-F., & Ma, S.-P. (2013) · Fitoterapia · doi:10.1016/j.fitote.2013.07.009 · Cited by 84
“Evidence of increased oxidative stress in autopsy samples of substantia nigra in PD includes increased levels of malonyldialdehyde, lipid and cholesterol hydroperoxide [16,19].”
Rifampicin Attenuates the MPTP-Induced Neurotoxicity in Mouse Brain
Oida, Y., Kitaichi, K., Nakayama, H., Ito, Y., Fujimoto, Y., Shimazawa, M., Nagai, H., & Hara, H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.01.116 · Cited by 47
Metadata
- Authors
- Dexter, D. T., Holley, A. E., Flitter, W. D., Slater, T. F., Wells, F. R., Daniel, S. E., Lees, A. J., Jenner, P., & Marsden, C. D.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 1994-01
- Volume
- 9
- Issue
- 1
- Pages
- 92-97
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2025931289
- Cited by
- 407
- References
- 20
- FWCI
- 9.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.